Angstrom Pharmaceuticals

Angstrom Pharmaceuticals focuses on drug development for the treatment of metastatic diseases and hematologic malignancies. The company’s drugs provide CD44-binding peptides in clinical development for the treatment of ovarian cancer and chronic lymphocytic leukemia, enabling patients with cancer, diabetic retinopathy, and age-related macular degeneration to achieve improved clinical outcomes.